Uncategorized
Ocular Therapeutix to evaluate Dextenza in treatment of allergic conjunctivitis
Ocular Therapeutix has begun enrollment in a phase 3 safety and efficacy trial of Dextenza, an allergic conjunctivitis treatment candidate, the company announced in a press release.Dextenza (sustained-release dexamethasone 0.4 mg) is delivered to the ocular surface for up to 30 days via a bioresorbable intracanalicular depot.